Source: SCRIP CITELINE COMMERCIAL Jeeva’s founder and CEO talks to Scrip about how the firm’s clinical trial management platform does away with the need for
Source: PRWeb Remarkable progress in the development of cell and gene therapies (CGTx) has ignited hope for millions of patients battling debilitating human diseases including Central
Source: PM360online Enhancing patient engagement in rare disease support programs requires tailored strategies that leverage innovative approaches, including AI and decentralized trials: Personalized Communication: Utilize
Source: IG Living Magazine Research and development of orphan drugs is time-consuming and costly, and appropriate participants for clinical trials are hard to find. Efficiently
Source: PR Web President Biden’s loss of his beloved son to brain cancer in 2015 inspired the Cancer Moonshot initiative. Dr. Harsha Rajasimha’s inspiration for
Source: PRWeb Jeeva Clinical Trials is revolutionizing drug development by integrating AI and automated workflows into clinical trials, significantly reducing the time and cost of
Source: Western Pennsylvania Healthcare News The recent Food and Drug Administration (FDA) approval of cell-based gene therapies for Sickle Cell Disease (SCD) marks a groundbreaking
Source: Rare Disease and Orphan Drug Journal Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and
Source: Dermatology Times Gender gaps, with consistent underrepresentation of females, present a substantial challenge in clinical research.(1) Achieving a balanced representation of both genders has
Source: The Company of Biologists Rare diseases affect only a few people in a given population but, collectively, they impact over 400 million people globally
Jeeva Clinical Trials Inc.
